Aimmune Therapeutics Inc. (NASDAQ:AIMT) does about 1.11M shares in volume on a normal day but saw 44609009 shares change hands in Monday trading. The company now has a market cap of 2.13B USD and an enterprise value of about $613.98M. Its current market price is $34.22, marking an increase of 171.59% compared to the previous close of $12.60. The 52 week high reached by this stock is $37.00 whilst the lowest price level in 52 weeks is $10.09. The script in recent trading has seen the stock touch a high of $34.28 and a low of $34.15.
Aimmune Therapeutics Inc. (AIMT) has a 20-day trading average at $14.36 and the current price is -7.51% off the 52-week high compared with 239.15% distance from its 52-week low. The 50-day simple moving average of the closing price is $15.33 and its 200-day simple moving average is $21.26. If we look at the stock’s price movements over the week, volatility stands at 4.30%, which increases to 4.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 89.34 to suggest the stock is overbought.
11 analysts observing the Aimmune Therapeutics Inc. (AIMT) stock have set the 12-month price targets for the company’s shares at between $15.00 and $50.00. The median price target is 0.81% away from the current levels at $34.50.
FactSet Research has provided data showing that 11 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 4 analysts have rated it as a buy and 6 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 13, 2020 when Cowen initiated the stock to “Outperform” and issued a price target of $35.
The current price level is 156.64%, 128.04%, and 61.20% away from its SMA20, SMA50, and SMA200 respectively, with the AIMT price moving below the 50-day SMA on August 31. Aimmune Therapeutics Inc. (AIMT) stock is up 174.20% over the week and 159.05% over the past month. Its price is 2.24% year-to-date and 71.44% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$1.06 above consensus estimates by $0.03. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.98 and -$4.26 for whole year. AIMT’s earnings per share are forecast to shrink by -7.30% this year and 32.60% over next year. Expected sales for next quarter are $5.19 million, which analysts say will come at $7.95 million for the current fiscal year and next year at $97.55 million. In addition, estimates put the company’s current quarterly revenue at an average of $1.94 million.
Its 12-month price target is $34.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $15.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $50.00.
Outstanding shares total 65.18M with insiders holding 20.86% of the shares and institutional holders owning 82.85% of the company’s common stock. The company has a return on equity of -170.90%. The beta has a value of 0.77. Price to book ratio is 12.40 and price to sales ratio is 3552.04.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has reduced its position in Aimmune Therapeutics Inc. (AIMT) to 3,056,571 shares, mirroring a recent drop by -0.99%. SPDR S&P Biotech ETF dumped 30618.0 shares of Aimmune Therapeutics Inc. common stock bringing its total worth to about $40.38 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by Eventide Healthcare & Life Scienc, which added 0.77 million shares to end up with 2,050,000 shares worth $27.08 million. Catalyst Eventide Gilead Fund cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 2.76% position in Aimmune Therapeutics Inc. thanks to 1.8 million shares amounting to $23.79 million.